Navigation Links
Amerigen Pharmaceuticals and Stason Pharmaceuticals Enter Into Collaboration Agreement for Development of Generic Oral Oncology Products
Date:10/18/2011

EAST BRUNSWICK, N.J. and IRVINE, Calif., Oct. 18, 2011 /PRNewswire/ -- Amerigen Pharmaceuticals Limited and Stason Pharmaceuticals Inc. today announced they had entered into a collaboration agreement regarding the development of generic oral oncology products. Under the terms of the agreement, Stason will use its specialized containment facilities and formulation expertise to develop and manufacture products for Amerigen to commercialize in the United States and other territories. Stason received an up-front fee and is eligible for additional product-specific development milestones, plus manufacturing revenues and royalties on any commercialized products.

"This deal allows Amerigen to broaden the range of specialty oral products within its development portfolio," said Jonathan Embleton, Chief Business Officer for Amerigen. "We look forward to working with Stason to bring generic versions of some important critical care products to market and we are especially pleased to announce the concurrent filing of the first ANDA from this collaboration."

"We have been working hard to leverage our high containment development and manufacturing capabilities," said Jim Fang, Chief Operating Officer for Stason. "This opportunity allows Stason to fully develop and commercialize our pipeline of generic oral oncology products. We look forward to working with Amerigen to accomplish this goal." 

About Amerigen

Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in East Brunswick, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Limited, is located in Suzhou, Jiangsu Province. The group has an active portfolio of products under development, filed, o
'/>"/>

SOURCE Amerigen Pharmaceuticals Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Belgium , Sept. 1, 2015 VolitionRx ... on developing blood-based diagnostic tests for a broad range of ... Executive Officer, Cameron Reynolds , is scheduled to attend ... is being held September 9-10, 2015 in Boston, ... on September 10. Wells Fargo Securities Research ...
(Date:9/1/2015)... , Sept. 1, 2015 Sargas ... Management (CCM) and Drug Adherence m Health applications ... automate the process of non face-to-face monitoring of ... this new release of our apps, doctors are ... services along with our ONCHIT certified Physician, Pharmacy ...
(Date:9/1/2015)... Sept. 1, 2015   Ivenix Inc. , ... management system, closed on a $42M round of ... Ventures. Cardinal Partners, CICA, Inc., Easterly Capital, Fidelity ... the round. This financing will support the company,s ... Leerink Partners LLC acted as the exclusive placement ...
Breaking Medicine Technology:VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 3VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 4SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3
... telangiectasia-like disease and Nijmegen breakage syndrome offer ... and cancer vulnerability in people carrying the ... Scientists at St. Jude Children,s Research Hospital ... two related neurological diseases--ataxia telangiectasia-like disease (ATLD) ...
... MannKind Corporation (Nasdaq: MNKD ) ... equivalence of its commercial inhaler to the version of ... deliver AFRESA(TM), MannKind,s ultra rapid acting insulin that recently ... Bioequivalence of Clinical and Commercial Scale Inhalers Study 138 ...
Cached Medicine Technology:Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 2Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 3MannKind Reports Successful Completion of Device Bioequivalence Trial 2MannKind Reports Successful Completion of Device Bioequivalence Trial 3
(Date:9/1/2015)... ... 01, 2015 , ... USA Medical Card, a leading distributor ... coincide with back-to-school and the start of “sick season” for many households across ... children are sick an average of 8 to 12 times each school year. ...
(Date:9/1/2015)... ... September 01, 2015 , ... AdvantagePlusCaregivers.com® provides information on defining ... what to look for and expect when searching for resources, as well as ... Canoga Park, CA by CEO, Richard Weatherman and Co-Founder Piroska Zalkadi, AdvantagePlusCaregivers.com® grew ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... communications archiving solution integrated with Alfresco‘s enterprise content management system. PRO Archiver ... save millions of dollars in printing costs by digitizing vast amounts of ...
(Date:9/1/2015)... ... 01, 2015 , ... Elizabeth Callahan, MD, founder and medical director of ... to offer RADIESSE® filler treatment for volume loss in the hands. RADIESSE provides an ... in the hands, delivering smooth, natural-looking results that can last up to one year ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new episode of “Voices ... take a look at the topic of arthritis. There are over 100 different types ... interesting arthritis types and statistics in an effort to shed light on this important ...
Breaking Medicine News(10 mins):Health News:USA Medical Card Launches New FAQ Video During Back-to-School 2Health News:AdvantagePlusCaregivers.com® Launches New Website for Corporate and Franchisee Locations in 3 States 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 3Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3
... an issue than youngsters, tastes, studies find, , , MONDAY, April ... issue of supply than demand in the poorest parts of ... children in these rural areas are open to eating more ... not readily available and could become even less so if ...
... published in the April issue of the Journal ... large numbers of physician assistants and nurse practitioners ... hired by general surgery residency programs in the last ... these professionals continue to be in demand. Most have ...
... of Fit by Sara and Susan G. Komen for the Cure, ... DIEGO, April 20 Word is spreading about YOGA 4 THE ... have gathered together to stretch, deep breathe and meditate. Along ... $1,000 in donations for breast cancer. Susan G. Komen for the ...
... 20 The 7th annual FedEx/St. ... 16, 2009 at 7:00 p.m. at the InterContinental Miami Hotel ... premier pediatric cancer research centers. This year,s event will honor ... Thalia , for their generous support of children in need ...
... PAUL, Minn., April 20 More than 2,000 letter carriers ... Out Hunger on May 9, 2009 in an effort ... by the recession. Stamp Out Hunger is the ... locally supports Second Harvest Heartland, the Upper Midwest,s largest hunger-relief ...
... Australia and Israel has identified a genetic variation that ... The finding is published in the latest edition of ... Helen Leonard, who heads the Australian Rett Syndrome Study ... the finding was exciting in that it identifies a ...
Cached Medicine News:Health News:Kids and Veggies: Offer Them and They Will Eat 2Health News:Surgical education programs have demand for physician assistants and nurse practitioners 2Health News:YOGA 4 THE CURE Raises $1,000 for Breast Cancer 2Health News:YOGA 4 THE CURE Raises $1,000 for Breast Cancer 3Health News:7th Annual FedEx/St. Jude Angels & Stars Gala Announces 2009 Honorees Tommy Mottola & Thalia 2Health News:7th Annual FedEx/St. Jude Angels & Stars Gala Announces 2009 Honorees Tommy Mottola & Thalia 3Health News:7th Annual FedEx/St. Jude Angels & Stars Gala Announces 2009 Honorees Tommy Mottola & Thalia 4Health News:Letter Carriers to Deliver Hope for Those Impacted by Economy 2Health News:Letter Carriers to Deliver Hope for Those Impacted by Economy 3Health News:New insight into Rett syndrome severity 2
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... are manufactured using the highest ... CQ UV PMMA material is ... single piece lenses. Unioptic lens ... nonphaco and phaco styles. All ...
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
... viscoelastic agent for the surgeon who performs ... Amvisc possesses sufficient viscosity for excellent chamber ... cohesive so that complete removal at the ... quickly accomplished. Amvisc is priced to compete ...
Medicine Products: